The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...

Additionally, new exploratory analyses will be presented from the pivotal EV-302 trial with PADCEV ® (enfortumab vedotin) in combination with KEYTRUDA ® (pembrolizumab) in patients with ...

This study investigated skeletal muscle loss and sarcopenia in patients with metastatic urothelial cancer receiving enfortumab vedotin and pembrolizumab therapy.

“The take-home message is that enfortumab-vedotin and pembrolizumab together in the frontline setting in metastatic urothelial cancer continues to maintain its transformative benefit over ...

Enfortumab vedotin-ejfv and pembrolizumab show superior PFS and OS compared to chemotherapy in urothelial carcinoma. The combination therapy's benefits are consistent across subgroups, including ...

Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.

However, enfortumab vedotin with or without pembrolizumab has been identified as a regimen of interest for these patients with upper tract urothelial cancer, explained Evangelia Vlachou, MD, a ...

Among patients with upper tract urothelial carcinoma (UTUC) lesions, the combination of Padcev (enfortumab vedotin) and Keytruda (pembrolizumab) resulted in promising clinical activity, study results ...

The approval of enfortumab vedotin in combination with pembrolizumab represents the first treatment regimen in the past 20-30 years that has shown superiority over platinum-based chemotherapy in the ...